Inicio
Autor Isabel Cristina Ramírez Sánchez
|
Comentario :
Médica Internista Infectóloga, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (32)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaAssociation between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy / Isabel Cristina Ramírez Sánchez ; Flórez Riaño, Ariel Fernando ; Rojas Castro, Oscar Julián ; Ospina, Sigifredo
Título : Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Autor ; Flórez Riaño, Ariel Fernando, Autor ; Rojas Castro, Oscar Julián, Autor ; Ospina, Sigifredo, Autor Fecha de publicación : 2025 Títulos uniformes : Journal of Infection and Chemotherapy Idioma : Español (spa) Idioma original : Inglés (eng) Palabras clave : Bloodstream infection; Carbapenem resistance; Empirical treatment; Febrile neutropenia; Gram-negative bacilli; Inappropriate therapy; Mortality Resumen : Background and objective: Inappropriate initial antimicrobial therapy has been associated with high mortality in patients with gram-negative bacilli bloodstream infections during febrile neutropenia following chemotherapy for hematological malignancies. The aim of this study is to determine this association in our hospital. Methods: A single center, retrospective, cohort study of bloodstream infection due to gram-negative bacilli and febrile neutropenia was conducted. Clinical characteristics, microbiological etiology, antimicrobial resistance profile, empirical and targeted antibiotic therapy, intensive care unit admission, persistent bacteremia and mortality were analyzed. Results: Of the 171 episodes of bloodstream infection due to gram-negative bacilli, empirical antimicrobial therapy was inappropriate in 43 episodes (25.1 %). There was a significant difference in mortality at 7 and 30 days between patients who received appropriate versus inappropriate empirical treatment (4.6 % versus 13.9 %, p = 0.04; 15.6 % versus 32.5 %, p = 0.016). Inappropriate empirical treatment (RR, 2.97 [95 % CI, 1.01–8.74]), shock at the time of febrile neutropenia diagnosis (RR, 6.5 [95 % CI, 1.83–23.05]) carbapenem-resistant microorganism (RR, 3.73 [95 % CI, 1.14–12.24]) and persistent bacteremia (RR, 84.6 [95 % CI, 11.3–629.4]) were associated with an increased mortality at 7 and 30 days. In the multivariate analysis, shock (RR, 4.85 [95 % CI, 2.10–11.65]) was independently associated with increased 30-day mortality, but inappropriate empirical antimicrobial therapy was not an independent prognostic determinant (RR, 1.66 [0.53–4.82]). Conclusion: Shock at the time of febrile neutropenia diagnosis contributes to mortality in patients with gram-negative bacilli bloodstream infection, in this scenario, appropriate empirical antimicrobial therapy should be encouraged. © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control Mención de responsabilidad : Flórez Riaño, Ariel Fernando, Rojas Castro, Oscar Julián, Ospina, Sigifredo, Ramírez-Sánchez, Isabel Cristina Referencia : Revista de Infecciones y Quimioterapia Volumen 31, Número 2 ,Febrero de 2025, 102538 DOI (Digital Object Identifier) : 10.1016/j.jiac.2024.10.006 PMID : 39396607 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/abs/pii/S1341321X24002794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy [documento electrónico] / Isabel Cristina Ramírez Sánchez, Autor ; Flórez Riaño, Ariel Fernando, Autor ; Rojas Castro, Oscar Julián, Autor ; Ospina, Sigifredo, Autor . - 2025.
Obra : Journal of Infection and Chemotherapy
Idioma : Español (spa) Idioma original : Inglés (eng)
Palabras clave : Bloodstream infection; Carbapenem resistance; Empirical treatment; Febrile neutropenia; Gram-negative bacilli; Inappropriate therapy; Mortality Resumen : Background and objective: Inappropriate initial antimicrobial therapy has been associated with high mortality in patients with gram-negative bacilli bloodstream infections during febrile neutropenia following chemotherapy for hematological malignancies. The aim of this study is to determine this association in our hospital. Methods: A single center, retrospective, cohort study of bloodstream infection due to gram-negative bacilli and febrile neutropenia was conducted. Clinical characteristics, microbiological etiology, antimicrobial resistance profile, empirical and targeted antibiotic therapy, intensive care unit admission, persistent bacteremia and mortality were analyzed. Results: Of the 171 episodes of bloodstream infection due to gram-negative bacilli, empirical antimicrobial therapy was inappropriate in 43 episodes (25.1 %). There was a significant difference in mortality at 7 and 30 days between patients who received appropriate versus inappropriate empirical treatment (4.6 % versus 13.9 %, p = 0.04; 15.6 % versus 32.5 %, p = 0.016). Inappropriate empirical treatment (RR, 2.97 [95 % CI, 1.01–8.74]), shock at the time of febrile neutropenia diagnosis (RR, 6.5 [95 % CI, 1.83–23.05]) carbapenem-resistant microorganism (RR, 3.73 [95 % CI, 1.14–12.24]) and persistent bacteremia (RR, 84.6 [95 % CI, 11.3–629.4]) were associated with an increased mortality at 7 and 30 days. In the multivariate analysis, shock (RR, 4.85 [95 % CI, 2.10–11.65]) was independently associated with increased 30-day mortality, but inappropriate empirical antimicrobial therapy was not an independent prognostic determinant (RR, 1.66 [0.53–4.82]). Conclusion: Shock at the time of febrile neutropenia diagnosis contributes to mortality in patients with gram-negative bacilli bloodstream infection, in this scenario, appropriate empirical antimicrobial therapy should be encouraged. © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control Mención de responsabilidad : Flórez Riaño, Ariel Fernando, Rojas Castro, Oscar Julián, Ospina, Sigifredo, Ramírez-Sánchez, Isabel Cristina Referencia : Revista de Infecciones y Quimioterapia Volumen 31, Número 2 ,Febrero de 2025, 102538 DOI (Digital Object Identifier) : 10.1016/j.jiac.2024.10.006 PMID : 39396607 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/abs/pii/S1341321X24002794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002324 AC-2025-007 Archivo digital Producción Científica Artículos científicos Disponible
Título : Histoplasma capsulatum tenosynovitis: An unusual presentation in a kidney transplant recipient Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Autor ; Alza Arcila, Jhongert, Autor ; Diaz Sanabria, Ricardo Augusto, Autor Fecha de publicación : 2024 Títulos uniformes : Transplant Infectious Disease Idioma : Inglés (eng) Palabras clave : Histoplasma capsulatum; kidney; tenosynovitis; transplantation. Resumen : Histoplasmosis is an expected endemic mycosis in solid organ transplant recipients and occurs as a primary infection, reactivation, or, rarely, acquired from an infected allograft. Reactivation is favored by maintenance immunosuppression or anti-rejection therapy, which facilitates the appearance of disseminated forms as well as unusual presentations. We present the case of a 66-year-old woman with isolated tenosynovitis due to Histoplasma capsulatum 25 years after a kidney transplant. Mención de responsabilidad : Jhongert Alza-Arcila, Isabel Cristina Ramírez-Sánchez, Ricardo Augusto Diaz-Sanabria DOI (Digital Object Identifier) : https://doi.org/10.1111/tid.14269 Derechos de uso : CC BY-NC-ND En línea : https://onlinelibrary.wiley.com/doi/full/10.1111/tid.14269 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Histoplasma capsulatum tenosynovitis: An unusual presentation in a kidney transplant recipient [documento electrónico] / Isabel Cristina Ramírez Sánchez, Autor ; Alza Arcila, Jhongert, Autor ; Diaz Sanabria, Ricardo Augusto, Autor . - 2024.
Obra : Transplant Infectious Disease
Idioma : Inglés (eng)
Palabras clave : Histoplasma capsulatum; kidney; tenosynovitis; transplantation. Resumen : Histoplasmosis is an expected endemic mycosis in solid organ transplant recipients and occurs as a primary infection, reactivation, or, rarely, acquired from an infected allograft. Reactivation is favored by maintenance immunosuppression or anti-rejection therapy, which facilitates the appearance of disseminated forms as well as unusual presentations. We present the case of a 66-year-old woman with isolated tenosynovitis due to Histoplasma capsulatum 25 years after a kidney transplant. Mención de responsabilidad : Jhongert Alza-Arcila, Isabel Cristina Ramírez-Sánchez, Ricardo Augusto Diaz-Sanabria DOI (Digital Object Identifier) : https://doi.org/10.1111/tid.14269 Derechos de uso : CC BY-NC-ND En línea : https://onlinelibrary.wiley.com/doi/full/10.1111/tid.14269 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002166 AC-2024-019 Archivo digital Producción Científica Artículos científicos Disponible
Título : Intussusception as the first manifestation of disseminated aspergillosis in a patient with autologous hematopoietic stem cell transplantation Tipo de documento : documento electrónico Autores : Diaz Sanabria, Ricardo Augusto, Autor ; Isabel Cristina Ramírez Sánchez, Autor Fecha de publicación : 2024 Títulos uniformes : Transplant infectious disease Idioma : Inglés (eng) Referencia : Diaz-Sanabria RA, Ramírez-Sánchez IC. Intussusception as the first manifestation of disseminated asp DOI (Digital Object Identifier) : 10.1111/tid.14265 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/38488811/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Intussusception as the first manifestation of disseminated aspergillosis in a patient with autologous hematopoietic stem cell transplantation [documento electrónico] / Diaz Sanabria, Ricardo Augusto, Autor ; Isabel Cristina Ramírez Sánchez, Autor . - 2024.
Obra : Transplant infectious disease
Idioma : Inglés (eng)
Referencia : Diaz-Sanabria RA, Ramírez-Sánchez IC. Intussusception as the first manifestation of disseminated asp DOI (Digital Object Identifier) : 10.1111/tid.14265 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/38488811/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002165 AC-2024-018 Archivo digital Producción Científica Artículos científicos Disponible
Título : Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Fecha de publicación : 2022 Títulos uniformes : The Lancet Infectious Diseases Idioma : Inglés (eng) Resumen : Background: Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primary regimens with the only approved dengue vaccine CYD-TDV (Dengvaxia; Sanofi Pasteur, Lyon, France) in individuals aged 9 years and older with previous dengue exposure. In this study, we assessed the need for a CYD-TDV booster after these primary vaccination regimens. Methods: In this randomised, controlled, phase 2, non-inferiority study, healthy individuals aged 9–50 years recruited from three sites in Colombia and three sites in the Philippines (excluding those with the usual contraindications to vaccinations) were randomly assigned 1:1:1 via a permuted block method with stratification by site and by age group using an independent voice response system to receive, at 6-month intervals, three doses of CYD-TDV (three-dose group), one dose of placebo followed by two doses of CYD-TDV (two-dose group), or two doses of placebo followed by one dose of CYD-TDV (one-dose group). Participants were also randomly assigned (1:1) to receive a CYD-TDV booster at 1 year or 2 years after the last primary dose. Each CYD-TDV dose was 0·5 mL and administered subcutaneously in the deltoid region of the upper arm. The investigators and sponsor, study staff interacting with the investigators, and participants and their parents or legally acceptable representatives were masked to group assignment. Neutralising antibodies were measured by 50% plaque reduction neutralisation testing, and geometric mean titres (GMTs) were calculated. Due to a change in study protocol, only participants who were dengue seropositive at baseline in the Colombian cohort received a booster vaccination. The primary outcome was to show non-inferiority of the booster dose administered at 1 year or 2 years after the two-dose and three-dose primary regimens; non-inferiority was shown if the lower limit of the two-sided adjusted 95% CI of the between-group (day 28 post-booster dose GMT from the three-dose or two-dose group vs day 28 GMT post-dose three of the three-dose primary regimen [three-dose group]) geometric mean ratio (GMR) was higher than 0·5 for each serotype. Non-inferiority of the 1-year or 2-year booster was shown if all four serotypes achieved non-inferiority. Safety was assessed among all participants who received the booster. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. Findings: Between May 2 and Sept 16, 2016, we recruited and enrolled 1050 individuals who received either vaccine or placebo. Of the 350, 348, and 352 individuals randomly assigned to three-dose, two-dose, and one-dose groups, respectively, 108, 115, and 115 from the Colombian cohort were dengue seropositive at baseline and received a booster; 55 and 53 in the three-dose group received a booster after 1 year and 2 years, respectively, as did 59 and 56 in the two-dose group, and 62 and 53 in the one-dose group. After the three-dose primary schedule, non-inferiority was shown for serotypes 2 (GMR 0·746; 95% CI 0·550–1·010) and 3 (1·040; 0·686–1·570) but not serotypes 1 (0·567; 0·399–0·805) and 4 (0·647; 0·434–0·963) for the 1-year booster, and again for serotypes 2 (0·871; 0·673–1·130) and 3 (1·150; 0·887–1·490) but not serotypes 1 (0·688; 0·479–0·989) and 4 (0·655; 0·471–0·911) for the 2-year booster. Similarly, after the two-dose primary schedule, non-inferiority was shown for serotypes 2 (0·809; 0·505–1·300) and 3 (1·19; 0·732–1·940) but not serotypes 1 (0·627; 0·342–1·150) and 4 (0·499; 0·331–0·754) for the 1-year booster, and for serotype 3 (0·911; 0·573–1·450) but not serotypes 1 (0·889; 0·462–1·710), 2 (0·677; 0·402–1·140), and 4 (0·702; 0·447–1·100) for the 2-year booster. Thus, non-inferiority of the 1-year or 2-year booster was not shown after the three-dose or two-dose primary vaccination regimen in dengue-seropositive participants. No safety concerns occurred with the 1-year or 2-year CYD-TDV booster. Interpretation: CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen does not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who are seropositive for dengue at baseline. Mención de responsabilidad : Diana Leticia Coronel-Martinez, Juliana Park, Eduardo López-Medina, María Rosario Capeding, Andrés Angelo Cadena Bonfanti, María Cecilia Montalbán, Isabel Ramírez, María Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramírez, Mae Ann Verdan, Fernando Noriega Referencia : Lancet Infect Dis. 2022 Jun;22(6):901-911. DOI (Digital Object Identifier) : 10.1016/S1473-3099(21)00706-4 PMID : 35364022 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1473309921007064 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study [documento electrónico] / Isabel Cristina Ramírez Sánchez, . - 2022.
Obra : The Lancet Infectious Diseases
Idioma : Inglés (eng)
Resumen : Background: Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primary regimens with the only approved dengue vaccine CYD-TDV (Dengvaxia; Sanofi Pasteur, Lyon, France) in individuals aged 9 years and older with previous dengue exposure. In this study, we assessed the need for a CYD-TDV booster after these primary vaccination regimens. Methods: In this randomised, controlled, phase 2, non-inferiority study, healthy individuals aged 9–50 years recruited from three sites in Colombia and three sites in the Philippines (excluding those with the usual contraindications to vaccinations) were randomly assigned 1:1:1 via a permuted block method with stratification by site and by age group using an independent voice response system to receive, at 6-month intervals, three doses of CYD-TDV (three-dose group), one dose of placebo followed by two doses of CYD-TDV (two-dose group), or two doses of placebo followed by one dose of CYD-TDV (one-dose group). Participants were also randomly assigned (1:1) to receive a CYD-TDV booster at 1 year or 2 years after the last primary dose. Each CYD-TDV dose was 0·5 mL and administered subcutaneously in the deltoid region of the upper arm. The investigators and sponsor, study staff interacting with the investigators, and participants and their parents or legally acceptable representatives were masked to group assignment. Neutralising antibodies were measured by 50% plaque reduction neutralisation testing, and geometric mean titres (GMTs) were calculated. Due to a change in study protocol, only participants who were dengue seropositive at baseline in the Colombian cohort received a booster vaccination. The primary outcome was to show non-inferiority of the booster dose administered at 1 year or 2 years after the two-dose and three-dose primary regimens; non-inferiority was shown if the lower limit of the two-sided adjusted 95% CI of the between-group (day 28 post-booster dose GMT from the three-dose or two-dose group vs day 28 GMT post-dose three of the three-dose primary regimen [three-dose group]) geometric mean ratio (GMR) was higher than 0·5 for each serotype. Non-inferiority of the 1-year or 2-year booster was shown if all four serotypes achieved non-inferiority. Safety was assessed among all participants who received the booster. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. Findings: Between May 2 and Sept 16, 2016, we recruited and enrolled 1050 individuals who received either vaccine or placebo. Of the 350, 348, and 352 individuals randomly assigned to three-dose, two-dose, and one-dose groups, respectively, 108, 115, and 115 from the Colombian cohort were dengue seropositive at baseline and received a booster; 55 and 53 in the three-dose group received a booster after 1 year and 2 years, respectively, as did 59 and 56 in the two-dose group, and 62 and 53 in the one-dose group. After the three-dose primary schedule, non-inferiority was shown for serotypes 2 (GMR 0·746; 95% CI 0·550–1·010) and 3 (1·040; 0·686–1·570) but not serotypes 1 (0·567; 0·399–0·805) and 4 (0·647; 0·434–0·963) for the 1-year booster, and again for serotypes 2 (0·871; 0·673–1·130) and 3 (1·150; 0·887–1·490) but not serotypes 1 (0·688; 0·479–0·989) and 4 (0·655; 0·471–0·911) for the 2-year booster. Similarly, after the two-dose primary schedule, non-inferiority was shown for serotypes 2 (0·809; 0·505–1·300) and 3 (1·19; 0·732–1·940) but not serotypes 1 (0·627; 0·342–1·150) and 4 (0·499; 0·331–0·754) for the 1-year booster, and for serotype 3 (0·911; 0·573–1·450) but not serotypes 1 (0·889; 0·462–1·710), 2 (0·677; 0·402–1·140), and 4 (0·702; 0·447–1·100) for the 2-year booster. Thus, non-inferiority of the 1-year or 2-year booster was not shown after the three-dose or two-dose primary vaccination regimen in dengue-seropositive participants. No safety concerns occurred with the 1-year or 2-year CYD-TDV booster. Interpretation: CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen does not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who are seropositive for dengue at baseline. Mención de responsabilidad : Diana Leticia Coronel-Martinez, Juliana Park, Eduardo López-Medina, María Rosario Capeding, Andrés Angelo Cadena Bonfanti, María Cecilia Montalbán, Isabel Ramírez, María Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramírez, Mae Ann Verdan, Fernando Noriega Referencia : Lancet Infect Dis. 2022 Jun;22(6):901-911. DOI (Digital Object Identifier) : 10.1016/S1473-3099(21)00706-4 PMID : 35364022 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1473309921007064 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001856 AC-2022-024 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos Otros títulos : Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, ; Carlos Esteban Builes Montaño, ; Alejandro Vélez Hoyos, Fecha de publicación : 2022 Títulos uniformes : Medicina & Laboratorio Idioma : Español (spa) Palabras clave : COVID-19 vacuna ARN mensajero adenovirus tiroiditis bocio Resumen : La enfermedad por coronavirus SARS-CoV-2 que surgió en el año 2019 (COVID-19), ha obligado al rápido desarrollo de vacunas para prevenir su propagación e intentar controlar la pandemia. Dentro de las vacunas desarrolladas, las primeras en ser aprobadas con una tecnología nueva en el campo de la vacunación, fueron las vacunas basadas en ARNm (ácido ribonucleico mensajero), que lograron tasas de efectividad cercanas al 95 % para la prevención de la enfermedad COVID-19 grave. Los eventos adversos comunes son reacciones locales leves, pero ha habido varios informes de pacientes que desarrollaron tiroiditis subaguda y disfunción tiroidea después de recibir la vacuna contra SARS-CoV-2. Este artículo presenta dos casos de tiroiditis subaguda poco después de recibir la vacuna contra COVID-19. Mención de responsabilidad : Myriam Vanessa Rueda-Galvis, Isabel Cristina Ramírez-Sánchez, Carlos E. Builes-Montaño, Alejandro Vélez-Hoyos DOI (Digital Object Identifier) : 10.36384/01232576.609 Derechos de uso : CC BY-NC-ND En línea : https://medicinaylaboratorio.com/index.php/myl/article/view/609 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos = Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases [documento electrónico] / Isabel Cristina Ramírez Sánchez, ; Carlos Esteban Builes Montaño, ; Alejandro Vélez Hoyos, . - 2022.
Obra : Medicina & Laboratorio
Idioma : Español (spa)
Palabras clave : COVID-19 vacuna ARN mensajero adenovirus tiroiditis bocio Resumen : La enfermedad por coronavirus SARS-CoV-2 que surgió en el año 2019 (COVID-19), ha obligado al rápido desarrollo de vacunas para prevenir su propagación e intentar controlar la pandemia. Dentro de las vacunas desarrolladas, las primeras en ser aprobadas con una tecnología nueva en el campo de la vacunación, fueron las vacunas basadas en ARNm (ácido ribonucleico mensajero), que lograron tasas de efectividad cercanas al 95 % para la prevención de la enfermedad COVID-19 grave. Los eventos adversos comunes son reacciones locales leves, pero ha habido varios informes de pacientes que desarrollaron tiroiditis subaguda y disfunción tiroidea después de recibir la vacuna contra SARS-CoV-2. Este artículo presenta dos casos de tiroiditis subaguda poco después de recibir la vacuna contra COVID-19. Mención de responsabilidad : Myriam Vanessa Rueda-Galvis, Isabel Cristina Ramírez-Sánchez, Carlos E. Builes-Montaño, Alejandro Vélez-Hoyos DOI (Digital Object Identifier) : 10.36384/01232576.609 Derechos de uso : CC BY-NC-ND En línea : https://medicinaylaboratorio.com/index.php/myl/article/view/609 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001906 AC-2022-070 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-070Adobe Acrobat PDF
PermalinkPermalink
Permalink
Permalink
Permalink
Permalink
PermalinkPermalink
PermalinkPermalink
